Product Description
Mechanisms of Action: NAMPT Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TopoTarget A/S
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Melanoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Mycosis Fungoides|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin|T-Cell Peripheral Lymphoma|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| APO866 for CTCL | P2 |
Completed |
Mycosis Fungoides|Lymphoma, B-Cell|T-Cell Cutaneous Lymphoma|Lymphoma, Non-Hodgkin |
2011-09-22 |
|
| AP3001 | P2 |
Completed |
T-Cell Peripheral Lymphoma|T-Cell Cutaneous Lymphoma |
2011-01-01 |
|
| 2006-000910-19 | P2 |
Completed |
Melanoma |
2009-03-24 |
|
| 2006-002850-31 | P2 |
Completed |
Chronic Lymphoid Leukemia |
2008-02-02 |